China forces R&D access in Danaher/GE biopharma deal

Danaher must provide research and development resources for an unfinished project related to the separation and purification of biomolecules as a condition for buying GE’s biopharma business, China’s competition watchdog has decided.


Get unlimited access to all Global Competition Review content